Startseite Lefty A is involved in sunitinib resistance of renal cell carcinoma cells via regulation of IL-8
Artikel
Lizenziert
Nicht lizenziert Erfordert eine Authentifizierung

Lefty A is involved in sunitinib resistance of renal cell carcinoma cells via regulation of IL-8

  • Ning Cui EMAIL logo , Qiang Han , Qizhen Cao , Kejun Wang , Xujia Zhou , Pingzhi Hou , Chao Liu , Lungang Chen und Lin Xu
Veröffentlicht/Copyright: 9. August 2021
Biological Chemistry
Aus der Zeitschrift Biological Chemistry Band 402 Heft 10

Abstract

Renal cell carcinoma (RCC) is the third most frequent malignancy within urological oncology. Sunitinib has been used as the standard of treatment for first-line RCC therapy. Understanding mechanisms of sunitinib resistance in RCC cell is important for clinical therapy and drug development. We established sunitinib resistant RCC cells by treating cells with increasing concentrations of sunitinib and named resistant cells as RCC/SR. Lefty A, an important embryonic morphogen, was increased in RCC/SR cells. Targeted inhibition of Lefty via its siRNAs restored the sensitivity of renal resistant cells to sunitinib treatment. It was due to that si-Lefty can decrease the expression of interleukin-8 (IL-8) in RCC/SR cells. Knockdown of IL-8 abolished Lefty-regulated sunitinib sensitivity of RCC cells. Mechanistically, Lefty can regulate IL-8 transcription via activation of p65, one major transcription factor of IL-8. Collectively, our present revealed that Lefty A can regulate sunitinib sensitivity of RCC cells of via NF-κB/IL-8 signals. It indicated that targeted inhibition of Lefty might be a potent approach to overcome sunitinib resistance of RCC.

Keywords: IL-8; Lefty; RCC; sunitinib
Corresponding author: Ning Cui, Medical Imaging Center, Taihe Hospital, No.32 Renmin South Road, Shiyan 442000, Hubei Province, China, E-mail:
Ning Cui and Qiang Han contributed equally to this work.

  1. Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

  2. Research funding: None declared.

  3. Conflict of interest statement: The authors declare no conflict of interest.

  4. Consent for publication: All authors give the consent for the publish of this study.

  5. Availability of data and material: All data and material are available.

References

Achermann, C., Stenner, F., and Rothschild, S.I. (2016). Treatment, outcome and prognostic factors in renal cell carcinoma - a single center study (2000-2010). J. Cancer 7: 921–927, https://doi.org/10.7150/jca.15228.Suche in Google Scholar PubMed PubMed Central

Akiya, M., Yamazaki, M., Matsumoto, T., Kawashima, Y., Oguri, Y., Kajita, S., Kijima, D., Chiba, R., Yokoi, A., Takahashi, H., et al.. (2017). Identification of LEFTY as a molecular marker for ovarian clear cell carcinoma. Oncotarget 8: 63646–63664, https://doi.org/10.18632/oncotarget.18882.Suche in Google Scholar PubMed PubMed Central

Bi, L.K., Zhou, N., Liu, C., Lu, F.D., Lin, T.X., Xuan, X.J., Jiang, C., Han, J.L., Huang, H., Zhang, C.X., et al.. (2014). Kidney cancer cells secrete IL-8 to activate Akt and promote migration of mesenchymal stem cells. Urol. Oncol.: Semin. Original 32: 607–612, https://doi.org/10.1016/j.urolonc.2013.10.018.Suche in Google Scholar PubMed

Brunen, D., Willems, S.M., Kellner, U., Midgley, R., Simon, I., and Bernards, R. (2013). TGF-beta an emerging player in drug resistance. Cell Cycle 12: 2960–2968, https://doi.org/10.4161/cc.26034.Suche in Google Scholar PubMed PubMed Central

Cavallari, C., Fonsato, V., Herrera, M.B., Bruno, S., Tetta, C., and Camussi, G. (2013). Role of Lefty in the anti tumor activity of human adult liver stem cells. Oncogene 32: 819–826, https://doi.org/10.1038/onc.2012.114.Suche in Google Scholar PubMed

Chen, R., Halder, G., Zhang, Z., and Mardon, G. (1999). Signaling by the TGF-beta homolog decapentaplegic functions reiteratively within the network of genes controlling retinal cell fate determination in Drosophila. Development 126: 935–943, https://doi.org/10.1242/dev.126.5.935.Suche in Google Scholar PubMed

Cheng, S.K., Olale, F., Brivanlou, A.H., and Schier, A.F. (2004). Lefty blocks a subset of TGFbeta signals by antagonizing EGF-CFC coreceptors. PLoS Biol. 2: E30, https://doi.org/10.1371/journal.pbio.0020030.Suche in Google Scholar PubMed PubMed Central

Corro, C., Healy, M.E., Engler, S., Bodenmiller, B., Li, Z., Schraml, P., Weber, A., Frew, I.J., Rechsteiner, M., and Moch, H. (2019). IL-8 and CXCR1 expression is associated with cancer stem cell-like properties of clear cell renal cancer. J. Pathol. 248: 377–389, https://doi.org/10.1002/path.5267.Suche in Google Scholar PubMed PubMed Central

Dai, C.L., Liang, Y.J., Wang, Y.S., Tiwari, A.K., Yan, Y.Y., Wang, F., Chen, Z.S., Tong, X.Z., and Fu, L.W. (2009). Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2. Cancer Lett. 279: 74–83, https://doi.org/10.1016/j.canlet.2009.01.027.Suche in Google Scholar PubMed

Derynck, R., Zhang, Y., and Feng, X.H. (1998). Smads: transcriptional activators of TGF-β responses. Cell 95: 737–740, https://doi.org/10.1016/s0092-8674(00)81696-7.Suche in Google Scholar PubMed

Dvash, T., Sharon, N., Yanuka, O., and Benvenisty, N. (2007). Molecular analysis of LEFTY-expressing cells in early human embryoid bodies. Stem Cell. 25: 465–472, https://doi.org/10.1634/stemcells.2006-0179.Suche in Google Scholar PubMed

Esteban, M.A., Bao, X., Zhuang, Q., Zhou, T., Qin, B., and Pei, D. (2012). The mesenchymal-to-epithelial transition in somatic cell reprogramming. Curr. Opin. Genet. Dev. 22: 423–428, https://doi.org/10.1016/j.gde.2012.09.004.Suche in Google Scholar PubMed

Hamada, H., Meno, C., Watanabe, D., and Saijoh, Y. (2002). Establishment of vertebrate left-right asymmetry. Nat. Rev. Genet. 3: 103–113, https://doi.org/10.1038/nrg732.Suche in Google Scholar PubMed

Huang, D., Ding, Y., Li, Y., Luo, W.M., Zhang, Z.F., Snider, J., Vandenbeldt, K., Qian, C.N., and Teh, B.T. (2010). Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma. Cancer Res 70: 1053–1062, https://doi.org/10.1158/0008-5472.can-09-3722.Suche in Google Scholar PubMed

Joosten, S.C., Hamming, L., Soetekouw, P.M., Aarts, M.J., Veeck, J., van Engeland, M., and Tjan-Heijnen, V.C. (2015). Resistance to sunitinib in renal cell carcinoma: from molecular mechanisms to predictive markers and future perspectives. Biochim. Biophys. Acta 1855: 1–16, https://doi.org/10.1016/j.bbcan.2014.11.002.Suche in Google Scholar PubMed

Jundi, K. and Greene, C.M. (2015). Transcription of Interleukin-8: how altered regulation can affect cystic fibrosis lung disease. Biomolecules 5: 1386–1398, https://doi.org/10.3390/biom5031386.Suche in Google Scholar PubMed PubMed Central

Liu, Y.N., Chang, T.H., Tsai, M.F., Wu, S.G., Tsai, T.H., Chen, H.Y., Yu, S.L., Yang, J.C.H., and Shih, J.Y. (2015). IL-8 confers resistance to EGFR inhibitors by inducing stem cell properties in lung cancer. Oncotarget 6: 10415–10431, https://doi.org/10.18632/oncotarget.3389.Suche in Google Scholar PubMed PubMed Central

Ma, J., Ren, Z., Ma, Y., Xu, L., Zhao, Y., Zheng, C., Fang, Y., Xue, T., Sun, B., and Xiao, W. (2009). Targeted knockdown of EGR-1 inhibits IL-8 production and IL-8-mediated invasion of prostate cancer cells through suppressing EGR-1/NF-κB synergy. J. Biol. Chem. 284: 34600–34606, https://doi.org/10.1074/jbc.m109.016246.Suche in Google Scholar

Markowitsch, S.D., Schupp, P., Lauckner, J., Vakhrusheva, O., Slade, K.S., Mager, R., Efferth, T., Haferkamp, A., and Juengel, E. (2020). Artesunate inhibits growth of sunitinib-resistant renal cell carcinoma cells through cell cycle arrest and induction of ferroptosis. Cancers 12, https://doi.org/10.3390/cancers12113150.Suche in Google Scholar PubMed PubMed Central

Matsumoto, T., Chino, H., Akiya, M., Hashimura, M., Yokoi, A., Tochimoto, M., Nakagawa, M., Jiang, Z., and Saegusa, M. (2020). Requirements of LEFTY and Nodal overexpression for tumor cell survival under hypoxia in glioblastoma. Mol. Carcinog. 59: 1409–1419, https://doi.org/10.1002/mc.23265.Suche in Google Scholar PubMed

Matsumoto, T., Yokoi, A., Hashimura, M., Oguri, Y., Akiya, M., and Saegusa, M. (2018). TGF--mediated LEFTY/Akt/GSK-3/Snail axis modulates epithelial-mesenchymal transition and cancer stem cell properties in ovarian clear cell carcinomas. Mol. Carcinog. 57: 957–967, https://doi.org/10.1002/mc.22816.Suche in Google Scholar PubMed

Meno, C., Ito, Y., Saijoh, Y., Matsuda, Y., Tashiro, K., Kuhara, S., and Hamada, H. (1997). Two closely-related left-right asymmetrically expressed genes, Lefty-1 and Lefty-2: their distinct expression domains, chromosomal linkage and direct neuralizing activity in Xenopus embryos. Gene Cell 2: 513–524, https://doi.org/10.1046/j.1365-2443.1997.1400338.x.Suche in Google Scholar PubMed

Oshimori, N., Oristian, D., and Fuchs, E. (2015). TGF-β promotes heterogeneity and drug resistance in squamous cell carcinoma. Cell 160: 963–976, https://doi.org/10.1016/j.cell.2015.01.043.Suche in Google Scholar PubMed PubMed Central

Peng, Q., Wang, L., Zhao, D., Lv, Y., Wang, H., Chen, G., Wang, J., and Xu, W. (2019). Overexpression of FZD1 is associated with a good prognosis and resistance of sunitinib in clear cell renal cell carcinoma. J. Cancer 10: 1237–1251, https://doi.org/10.7150/jca.28662.Suche in Google Scholar PubMed PubMed Central

Prud'homme, G.J. (2012). Cancer stem cells and novel targets for antitumor strategies. Curr. Pharmaceut. Des. 18: 2838–2849, https://doi.org/10.2174/138161212800626120.Suche in Google Scholar PubMed

Rossi, S.H., Klatte, T., Usher-Smith, J., and Stewart, G.D. (2018). Epidemiology and screening for renal cancer. World J. Urol. 36: 1341–1353, https://doi.org/10.1007/s00345-018-2286-7.Suche in Google Scholar PubMed PubMed Central

Saleeb, R.M., Farag, M., Lichner, Z., Brimo, F., Bartlett, J., Bjarnason, G., Finelli, A., Rontondo, F., Downes, M.R., and Yousef, G.M. (2018). Modulating ATP binding cassette transporters in papillary renal cell carcinoma type 2 enhances its response to targeted molecular therapy. Mol. Oncol. 12: 1673–1688, https://doi.org/10.1002/1878-0261.12346.Suche in Google Scholar PubMed PubMed Central

Seike, M., Kitamura, K., Miyanaga, A., Okano, T., Noro, R., and Gemma, A. (2014). Mir-134/487b/655 cluster regulates TGF-beta-induced epithelial-mesenchymal transition and drug resistance to gefitinib by targeting MAGI2 in lung adenocarcinoma cells. Cancer Res 74, https://doi.org/10.1158/1535-7163.MCT-13-0448.Suche in Google Scholar PubMed

Tanji, N. and Yokoyama, M. (2011). Treatment of metastatic renal cell carcinoma and renal pelvic cancer. Clin. Exp. Nephrol. 15: 331–338, https://doi.org/10.1007/s10157-011-0438-9.Suche in Google Scholar PubMed

Ulloa, L. and Tabibzadeh, S. (2001). Lefty inhibits receptor-regulated Smad phosphorylation induced by the activated transforming growth factor-β receptor. J. Biol. Chem. 276: 21397–21404, https://doi.org/10.1074/jbc.m010783200.Suche in Google Scholar

van der Mijn, J.C., Mier, J.W., Broxterman, H.J., and Verheul, H.M. (2014). Predictive biomarkers in renal cell cancer: insights in drug resistance mechanisms. Drug Resist. Updates 17: 77–88, https://doi.org/10.1016/j.drup.2014.10.003.Suche in Google Scholar PubMed

Wills, A.E. and Baker, J.C. (2015). E2a is necessary for Smad2/3-dependent transcription and the direct repression of Lefty during gastrulation. Dev. Cell 32: 345–357, https://doi.org/10.1016/j.devcel.2014.11.034.Suche in Google Scholar PubMed PubMed Central

Xu, X.D., Zhang, L., He, X.G., Zhang, P., Sun, C.H., Xu, X.J., Lu, Y.J., and Li, F.F. (2018). TGF-beta plays a vital role in triple-negative breast cancer (TNBC) drug-resistance through regulating sternness, EMT and apoptosis. Biochem. Biophys. Res. Commun. 502: 160–165, https://doi.org/10.1016/j.bbrc.2018.05.139.Suche in Google Scholar PubMed

Zabala, M., Lobo, N.A., Antony, J., Heitink, L.S., Gulati, G.S., Lam, J., Parashurama, N., Sanchez, K., Adorno, M., Sikandar, S.S., et al.. (2020). LEFTY1 is a dual-SMAD inhibitor that promotes mammary progenitor growth and tumorigenesis. Cell Stem Cell 27: 284–299 e288, https://doi.org/10.1016/j.stem.2020.06.017.Suche in Google Scholar PubMed

Zhang, Z., Jiang, T., Li, Q., Wang, J., Yang, D., Li, X., Wang, Q., and Song, X. (2015). Nodal activates smad and extracellular signal-regulated kinases 1/2 pathways promoting renal cell carcinoma proliferation. Mol. Med. Rep. 12: 587–594, https://doi.org/10.3892/mmr.2015.3343.Suche in Google Scholar PubMed

Zhou, N., Lu, F.D., Liu, C., Xu, K.W., Huang, J., Yu, D.X., and Bi, L.K. (2016). IL-8 induces the epithelial-mesenchymal transition of renal cell carcinoma cells through the activation of AKT signaling. Oncol. Lett. 12: 1915–1920, https://doi.org/10.3892/ol.2016.4900.Suche in Google Scholar PubMed PubMed Central

Received: 2021-04-25
Accepted: 2021-06-23
Published Online: 2021-08-09
Published in Print: 2021-09-27

© 2021 Walter de Gruyter GmbH, Berlin/Boston

Artikel in diesem Heft

  1. Frontmatter
  2. Review
  3. Biophysical applications in structural and molecular biology
  4. Research Articles/Short Communications
  5. Genes and Nucleic Acids
  6. Historic nucleic acids isolated by Friedrich Miescher contain RNA besides DNA
  7. Protein Structure and Function
  8. The extracellular region of bovine milk butyrophilin exhibits closer structural similarity to human myelin oligodendrocyte glycoprotein than to immunological BTN family receptors
  9. Structural insights into the repair mechanism of AGT for methyl-induced DNA damage
  10. Cell Biology and Signaling
  11. In vitro osteogenic activities of sulfated derivative of polysaccharide extracted from Tamarindus indica L.
  12. Synthesis and biological characterization of a new fluorescent probe for vesicular trafficking based on polyazamacrocycle derivative
  13. Properties of transmembrane helix TM1 of the DcuS sensor kinase of Escherichia coli, the stator for TM2 piston signaling
  14. Lefty A is involved in sunitinib resistance of renal cell carcinoma cells via regulation of IL-8
  15. Proteolysis
  16. Tissue factor pathway inhibitor 2 is a potent kallikrein-related protease 12 inhibitor
https://doi.org/10.1515/hsz-2021-0280
Schlagwörter für diesen Artikel
IL-8; Lefty; RCC; sunitinib

Artikel in diesem Heft

  1. Frontmatter
  2. Review
  3. Biophysical applications in structural and molecular biology
  4. Research Articles/Short Communications
  5. Genes and Nucleic Acids
  6. Historic nucleic acids isolated by Friedrich Miescher contain RNA besides DNA
  7. Protein Structure and Function
  8. The extracellular region of bovine milk butyrophilin exhibits closer structural similarity to human myelin oligodendrocyte glycoprotein than to immunological BTN family receptors
  9. Structural insights into the repair mechanism of AGT for methyl-induced DNA damage
  10. Cell Biology and Signaling
  11. In vitro osteogenic activities of sulfated derivative of polysaccharide extracted from Tamarindus indica L.
  12. Synthesis and biological characterization of a new fluorescent probe for vesicular trafficking based on polyazamacrocycle derivative
  13. Properties of transmembrane helix TM1 of the DcuS sensor kinase of Escherichia coli, the stator for TM2 piston signaling
  14. Lefty A is involved in sunitinib resistance of renal cell carcinoma cells via regulation of IL-8
  15. Proteolysis
  16. Tissue factor pathway inhibitor 2 is a potent kallikrein-related protease 12 inhibitor
Jetzt anmelden und 20% sparen
Institutioneller Zugang
Wie funktioniert Authentifizierung?
Haben Sie eine Idee, wie wir unsere Website verbessern können?
Bitte schreiben Sie uns.
© 2025 De Gruyter Brill
Heruntergeladen am 30.9.2025 von https://www.degruyterbrill.com/document/doi/10.1515/hsz-2021-0280/html
Button zum nach oben scrollen